Open Access

Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer

  • Authors:
    • Zhu Li
    • Xu Hou
    • Juan Chen
    • Huidong Sun
    • Yuetang Mi
    • Yongling Sui
    • Yuhong Li
    • Jiaping Xie
    • Yingli Qiao
    • Xiaofeng Lei
    • Xiaoshuang Che
    • Jun Liu
  • View Affiliations

  • Published online on: May 24, 2017     https://doi.org/10.3892/ol.2017.6240
  • Pages: 579-586
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated the clinical efficacy of S-1 plus oxaliplatin (SOX) regimen, with or without surgery in α-fetoprotein-producing gastric cancer (APGC) with liver metastasis. A total of 24 patients with APGC treated at the Liaocheng People's Hospital between January 2011 and December 2013 were retrospectively reviewed. Clinical efficacy and patient safety were compared between the two groups. The median progression‑free survival (PFS) and overall survival (OS) in the SOX group were 6.5 [95% confidence interval (CI), 4.6‑8.4] and 13.5 (95% CI, 8.1‑18.9) months, respectively. The corresponding indicators in the SOX and surgery group were 7.0 (95% CI, 5.7‑8.3) and 14 (95% CI, 11.0‑17.1) months, respectively. There was no significant difference in PFS and OS between the two groups (P=0.703 and 0.710, respectively). The adverse effects of leucopenia, neutropenia, anemia and diarrhea occurred in ~10% of patients in the SOX group and in 14.3% (2/14), 7.14% (1/14), 14.3% (2/14) and 7.14% (1/14), respectively, in the surgery group. No significant difference was identified between groups in terms of overall incidence of adverse effects (P=0.17). However, severe adverse events, including gastroplegia, pancreatic fistula, pulmonary infection and refractory ascites, occurred only in the SOX plus surgery group [incidence rate for severe adverse events, 7.14% (1/14); P<0.001 between groups]. In conclusion, SOX chemotherapy is safe and effective in patients with APGC and liver metastasis. However, the addition of surgery to SOX chemotherapy may not improve the disease control rate and may increase the adverse effects.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Z, Hou X, Chen J, Sun H, Mi Y, Sui Y, Li Y, Xie J, Qiao Y, Lei X, Lei X, et al: Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer. Oncol Lett 14: 579-586, 2017
APA
Li, Z., Hou, X., Chen, J., Sun, H., Mi, Y., Sui, Y. ... Liu, J. (2017). Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer. Oncology Letters, 14, 579-586. https://doi.org/10.3892/ol.2017.6240
MLA
Li, Z., Hou, X., Chen, J., Sun, H., Mi, Y., Sui, Y., Li, Y., Xie, J., Qiao, Y., Lei, X., Che, X., Liu, J."Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer". Oncology Letters 14.1 (2017): 579-586.
Chicago
Li, Z., Hou, X., Chen, J., Sun, H., Mi, Y., Sui, Y., Li, Y., Xie, J., Qiao, Y., Lei, X., Che, X., Liu, J."Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer". Oncology Letters 14, no. 1 (2017): 579-586. https://doi.org/10.3892/ol.2017.6240